Madison Avenue Partners, LP

13D and 13G Filings

Investors who own more than 5% of a class must file a Schedule 13D or 13G. The latest filing for each security since 12/18/2024, newest first.

Issuer % of Class Filed
Ultragenyx Pharmaceutical Inc. 13G
RARE · 90400D108
6.4% 10/20/2026
Event 10/13/2026
Theravance Biopharma, Inc. 13G/A
TBPH · G8807B106
17.7% 8/14/2026
Event 6/30/2026
Graham Holdings Co 13G
GHC · 384637104
7.5% 8/14/2026
Event 6/30/2026
Staar Surgical Co 13G/A
STAA · 852312305
8.4% 8/14/2026
Event 6/30/2026
Lakefront Biotherapeutics NV 13G
LKFT · 36315X101
5.5% 6/23/2026
Event 6/15/2026
Magnera Corporation 13G/A
MAGN · 55939A107
4.4% 5/15/2026
Event 3/31/2026
Indivior Pharmaceuticals, Inc. 13G/A
INDV · G4766E116
3.5% 5/15/2026
Event 3/31/2026
Apartment Investment & Management Co 13G
AIV · 03748R747
8.6% 3/4/2026
Event 2/26/2026
Keros Therapeutics, Inc. 13G/A
KROS · 492327101
2.7% 2/17/2026
Event 12/31/2025
Veradigm Inc. 13G
MDRX · 01988P108
6.6% 1/29/2026
Event 1/22/2026
CARGO Therapeutics, Inc. 13G/A
CRGX · 14179K101
0% 11/14/2025
Event 9/30/2025
Sage Therapeutics, Inc. 13G/A
SAGE · 78667J108
0% 11/14/2025
Event 9/30/2025
ACELYRIN, Inc. 13D
SLRN · 00445A100
5.1% 4/30/2025
Event 4/29/2025
Ovid Therapeutics Inc. 13G/A
OVID · 690469101
4.0% 2/14/2025
Event 12/31/2024
John Wiley & Sons, Inc. 13G/A
WLY · 968223206
4.95% 2/14/2025
Event 12/31/2024